PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China. yunlongcao@pku.edu.cn.\', \'Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, P. R. China. yunlongcao@pku.edu.cn.\', \'Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.\', \'School of Life Sciences, Peking University, Beijing, P. R. China.\', \'College of Chemistry and Molecular Engineering, Peking University, Beijing, P. R. China.\', \'Joint Graduate Program of Peking-Tsinghua-NIBS, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, P. R. China.\', \'Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.\', \'Tsinghua-Peking Center for Life Sciences, Beijing, P. R. China.\', \'Beijing YouAn Hospital, Capital Medical University, Beijing, P. R. China.\', \'Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.\', \'CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P. R. China. xiangxi@ibp.ac.cn.\', \'Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, P. R. China. junyuxiao@pku.edu.cn.\', \'School of Life Sciences, Peking University, Beijing, P. R. China. junyuxiao@pku.edu.cn.\', \'Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China. wangyc@nifdc.org.cn.\', \'Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China. sunneyxie@biopic.pku.edu.cn.\', \'Beijing Advanced Innovation Center for Genomics (ICG), Peking University, Beijing, P. R. China. sunneyxie@biopic.pku.edu.cn.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41586-021-04385-3
?:doi
?:hasPublicationType
?:journal
  • Nature
is ?:pmid of
?:pmid
?:pmid
  • 35016194
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 17.875
?:rankingScore_hIndex
  • 1052
?:title
  • Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35016194>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35016194>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all